Imunon, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing text does not provide a separate fourth-quarter income statement. Imunon is a clinical-stage biotechnology company developing non-viral DNA medicines and vaccines; it has no product sales.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Licensing revenue | $0 | $0.5 million |
| Research and development expense | $11.3 million | $11.7 million |
| General and administrative expense | $9.7 million | $13.7 million |
| Operating loss | $21.0 million | $24.9 million |
| Net loss | $19.5 million | $35.9 million |
| Net loss per share, basic and diluted | $2.16 | $5.03 |
| Net cash used in operating activities | $19.0 million | $23.1 million |
- At year-end, cash and cash equivalents were $5.8 million and short-term investments were $9.9 million. The company also reported a $1.3 million receivable from its New Jersey net operating loss sale; management described total available resources as approximately $17.0 million including that amount and interest receivable.
- Current assets were $18.2 million and current liabilities were $7.4 million, yielding $10.8 million of working capital. Total assets were $21.9 million and stockholders’ equity was $13.4 million.
- The $6.0 million Silicon Valley Bank loan was repaid in April 2023. No notes payable remained at year-end; operating lease liabilities totaled $1.6 million.
- No product-level margin is reported because the company has no product sales. Operating margins are not meaningful for this loss-making development-stage business.
Material changes and notable items
- Net loss narrowed by $16.4 million year over year, while operating expenses declined $4.4 million. Lower G&A and the absence of the prior-year $13.4 million non-cash in-process R&D impairment and $5.4 million non-cash earn-out liability gain helped make the year-over-year comparison unusual. Interest expense also fell from $5.0 million to $0.2 million, partly because preferred-offering costs had affected 2022.
- R&D spending shifted toward PlaCCine vaccine development, which rose to $4.5 million from $2.4 million; manufacturing and process-development costs increased to approximately $2.3 million from $1.2 million. Licensing revenue ended after the Hisun agreement was fully amortized in 2022.
- Imunon sold 1.9 million shares through its ATM program in 2023 for net proceeds of $2.8 million. Shares issued increased to 9.4 million at year-end from 7.4 million a year earlier.
- The company wrote off a $375,000 convertible note and related warrants after Transomic Technologies dissolved in December 2023.
Pipeline, outlook and risks
- IMNN-001: The lead ovarian cancer candidate is in Phase II development. In September 2023, preliminary OVATION 2 data indicated an approximately 33% delay in disease progression and an approximately nine-month improvement in overall survival for the treatment arm versus control. These were interim trends, not final results. The reported PARP-inhibitor subgroup was not prespecified. Topline OVATION 2 results were expected in mid-2024.
- A separate Phase I/II study of IMNN-001 with bevacizumab began enrolling in 2023; it is planned to enroll 50 patients. Timing for its endpoints depends on enrollment and follow-up.
- Vaccines: The company reported encouraging animal data for its PlaCCine platform. In March 2024, after the fiscal year-end, it submitted an IND for the seasonal COVID-19 booster candidate IMNN-101 and expected Phase I/II enrollment in Q2 2024. A three-year NIAID collaboration will evaluate Lassa virus vaccine candidates in animal models. These programs remain early-stage and have not established clinical efficacy.
- ThermoDox: The Phase III OPTIMA study was stopped after a 2020 interim analysis crossed the prespecified futility boundary; patient follow-up ended in 2021. The filing says retrospective subgroup findings were not pursued.
- Liquidity and going concern: Management estimated resources would fund operations into Q4 2024, but the company had no committed additional capital. Management and the auditor concluded substantial doubt exists about the company’s ability to continue as a going concern; the auditor’s report includes an explanatory paragraph. Planned funding through equity, debt, partnerships, licensing or other sources is uncertain and may dilute shareholders. The company has no product revenue and expects operating losses to continue.
- Listing and leadership: Nasdaq notified the company in December 2023 that its share price had been below the $1 minimum for 30 consecutive business days; the stated deadline to regain compliance was June 24, 2024. After year-end, CEO Corinne Le Goff resigned effective March 15, 2024; Executive Chairman Michael Tardugno assumed day-to-day leadership while a successor search proceeds.
- Other material risks include clinical and regulatory failure or delay, reliance on third-party trial operators and manufacturers, potential financing constraints and dilution, competition, intellectual-property challenges, reimbursement uncertainty, and stock-price volatility.
Important facts for investors to verify
- Current cash, investment balances, burn rate, financing activity and the company’s ability to fund operations beyond its stated runway.
- Final OVATION 2 results, including prespecified endpoint analyses, statistical significance, safety, and the interpretation of interim and subgroup findings.
- IMNN-101 IND status, trial initiation and enrollment, and the scope and results of the NIAID Lassa collaboration.
- Nasdaq bid-price compliance and any effect of further equity issuance on dilution and liquidity.
- CEO succession and the status or potential financial impact of the pending derivative shareholder lawsuit; the filing says its likelihood and potential loss cannot be estimated.